Eye Meds Now

 Quick Ophthalmic Drug Search

227 items found
TETRACAINE (tetracaine hydrochloride (0.5%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Anesthetic Medications
Indications/Usage:

Indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic.


Typical Dosing:  

 Rapid and short-acting topical ophthalmic anesthetic:

  • Topical administration:
    • 1 drop topically in the eye as needed. Discard unused portion.
  • Sterile field administration:
    • Open package using standard aseptic technique. The DROP-TAINER® dispenser may then be allowed to fall upon a sterile surface. The entire outer surface of the DROP-TAINER® dispenser and its contents are sterile.

How Supplied:  
  • 1 mL bottles
  • 4 mL bottles
  • 15 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 36° – 77°F (2° – 25°C).
  • Protect from light.
  • Do not use if solution contains crystals, is cloudy or is discolored.


TIMOPTIC (timolol maleate (0.25%; 0.5%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Beta Blocking Agents
Indications/Usage:

Indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.

TIMOPTIC IN OCUDOSE ONLY: May be used when a patient is sensitive to the preservative in TIMOPTIC® (timolol maleate ophthalmic solution), benzalkonium chloride, or when use of a preservative-free topical medication is advisable.


Typical Dosing:  

Elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma:

  • Ophthalmic solution:
    • Available in concentrations of 0.25% and 0.5%:
      • The usual starting dose is 1 drop of 0.25% in the affected eye(s) twice a day.
      • If the clinical response is not adequate, the dosage may be changed to 1 drop of 0.5% solution in the affected eye(s) twice a day.
    • Since in some patients the pressure-lowering response to TIMOPTIC may require a few weeks to stabilize, evaluation should include a determination of IOP after approximately 4 weeks of treatment with TIMOPTIC.
    • If the IOP is maintained at satisfactory levels, the dosage schedule may be changed to 1 drop once a day in the affected eye(s).
    • Because of diurnal variations in IOP, satisfactory response to the once-a-day dose is best determined by measuring the IOP at different times during the day.
    • Dosages above 1 drop of 0.5% TIMOPTIC twice a day generally have not been shown to produce further reduction in intraocular pressure.
    • If the patient's IOP is still not at a satisfactory level on this regimen, concomitant therapy with other agent(s) for lowering IOP can be instituted.
    • The concomitant use of two topical beta-adrenergic blocking agents is not recommended [See PRECAUTIONS, Drug Interactions, Beta-adrenergic blocking agents in package insert].
  • Ophthalmic solution in OCUDOSE:
    • Available in concentrations of 0.25% and 0.5%:
      • The usual starting dose is 1 drop of 0.25% in the affected eye(s) administered twice a day. Apply enough gentle pressure on the individual container to obtain a single drop of solution.
      • If the clinical response is not adequate, the dosage may be changed to 1 drop of 0.5% solution in the affected eye(s) administered twice a day.
    • Since in some patients the pressure-lowering response to Preservative-free TIMOPTIC in OCUDOSE may require a few weeks to stabilize, evaluation should include a determination of IOP after approximately 4 weeks of treatment with Preservative-free TIMOPTIC in OCUDOSE.
    • If the IOP is maintained at satisfactory levels, the dosage schedule may be changed to 1 drop once a day in the affected eye(s).
    • Because of diurnal variations in IOP, satisfactory response to the once-a-day dose is best determined by measuring the IOP at different times during the day.
    • Dosages above 1 drop of 0.5% TIMOPTIC (timolol maleate ophthalmic solution) twice a day generally have not been shown to produce further reduction in IOP.
    • If the patient's IOP is still not at a satisfactory level on this regimen, concomitant therapy with other agent(s) for lowering IOP can be instituted taking into consideration that the preparation(s) used concomitantly may contain one or more preservatives.
    • The concomitant use of 2 topical beta-adrenergic blocking agents is not recommended (See PRECAUTIONS, Drug Interactions, Beta-adrenergic blocking agents in package insert).
  • Additional information for keeping OCUDOSE solution sterile is in Notes below.

How Supplied:  
  • Ophthalmic solution:
    • 0.25% ophthalmic solution
      • 5 mL bottles
      • 10 mL bottles (generic only)
      • 15 mL bottles (generic only)
    • 0.5% ophthalmic solution
      • 2.5 mL bottles (generic only)
      • 5 mL bottles
      • 10 mL bottles
      • 15 mL bottles (generic only)
  • Ophthalmic solution in OCUDOSE (Preservative free):
    • 0.25% ophthalmic solution
      • 0.3 mL in 60 unit dose containers
    • 0.5% ophthalmic solution
      • 0.3 mL in 60 unit dose containers

Preservatives:  

benzalkonium chloride (ophthalmic solution); none listed in package insert (OCUDOSE).


Storage:  
  • Store at room temperature 59° – 77°F (15° – 25°C).
  • Protect from freezing.
  • Protect from light.
  • Ophthalmic solution in OCUDOSE: Because evaporation can occur through the unprotected polyethylene unit dose container and prolonged exposure to direct light can modify the product, the unit dose container should be kept in the protective foil overwrap and used within 1 month after the foil package has been opened.


Assistance: Payment Assistance

TIMOPTIC-XE (timolol maleate (0.25%; 0.5%) gel forming ophthalmic solution)
Prescription
Topical
Gel
Ophthalmic Solution
Beta Blocking Agents
Indications/Usage:

Indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.


Typical Dosing:  

Elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma:

  • Patients should be instructed to invert the closed container and shake once before each use. It is not necessary to shake the container more than once.
  • Other topically applied ophthalmic medications should be administered at least 10 minutes before TIMOPTIC-XE [See PRECAUTIONS, Information for Patients and accompanying INSTRUCTIONS FOR USE in package insert].
  • Available in concentrations of 0.25% and 0.5% (See PRECAUTIONS, Drug Interactions, Beta-adrenergic blocking agents in package insert):
    • The dose is 1 drop of TIMOPTIC-XE (either 0.25% or 0.5%) in the affected eye(s) once a day.
  • Because in some patients the pressure-lowering response to TIMOPTIC-XE may require a few weeks to stabilize, evaluation should include a determination of IOP after approximately 4 weeks of treatment with TIMOPTIC-XE.
  • Dosages higher than 1 drop of 0.5% TIMOPTIC-XE once a day have not been studied. If the patient's IOP is still not at a satisfactory level on this regimen, concomitant therapy can be considered.
  • The concomitant use of 2 topical beta-adrenergic blocking agents is not recommended [See PRECAUTIONS, Drug Interactions, Beta-adrenergic blocking agents in package insert].
  • When patients have been switched from therapy with TIMOPTIC administered 2 times daily to TIMOPTIC-XE administered 1 time daily, the ocular hypotensive effect has remained consistent.

How Supplied:  
  • 0.25% ophthalmic solution
    • 5 mL bottles
  • 0.5% ophthalmic solutuion
    • 5 mL bottles

Preservatives:  

benzododecinium bromide


Storage:  
  • Store at 59° – 77°F (15° – 25°C).
  • Avoid freezing.
  • Protect from light.


TOBRADEX (tobramycin (0.3%) – dexamethasone (0.1%) ophthalmic ointment; ophthalmic suspension)
Prescription
Topical
Ointment
Ophthalmic Suspension
Antibiotic–Steroid Combination Medications
Indications/Usage:

Indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. 

Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation.

They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies.

The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.

The particular anti-infective drug in this product is active against the following common bacterial eye pathogens:

Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains.

Streptococci, including some of the Group A beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae.

Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species.

This medication has a broad FDA approval for "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Steroid-responsive inflammatory ocular conditions:

  • Ophthalmic ointment:
    • Apply a small amount (approximately ½ inch ribbon) into the conjunctival sac(s) up to 3 – 4 times daily. 
    • How to apply:
      • Tilt your head back.
      • Place a finger on your cheek just under your eye and gently pull down until a "V” pocket is formed between your eyeball and your lower lid.
      • Place a small amount (about ½ inch) in the "V" pocket. Do not let the tip of the tube touch your eye.
      • Look downward before closing your eye.
    • Not more than 8 g should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS in package insert.
  • Ophthalmic suspension:
    • Instill 1 or 2 drops into the conjunctival sac(s) every 4 – 6 hours. 
    • During the initial 24 – 48 hours, the dosage may be increased to 1 or 2 drops every 2 hours.
    • Frequency should be decreased gradually as warranted by improvement in clinical signs. Care should be taken not to discontinue therapy prematurely.
    • Not more than 20 mL should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS in package insert.

How Supplied:  
  • Ophthalmic ointment:
    • 3.5 g tubes
  • Ophthalmic suspension:
    • 2.5 mL bottles
    • 5 mL bottles
    • 10 mL bottles

Preservatives:  

chlorobutanol (ophthalmic ointment);  benzalkonium chloride (ophthalmic suspension)


Storage:  
  • Ophthalmic ointment:
    • Store at 36° – 77°F (2° – 25°C).
  • Ophthalmic suspension:
    • Store suspension at 46° – 80°F (8° – 27°C).
    • Store suspension upright.
    • Shake suspension well before using.


TOBRADEX ST (tobramycin (0.3%) – dexamethasone (0.5%) ophthalmic suspension)
Prescription
Topical
Ophthalmic Suspension
Antibiotic–Steroid Combination Medications
Indications/Usage:

Indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation.  They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies.

The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.

The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant isolates. Streptococci, including some Group A and other beta-hemolytic species, some nonhemolytic Streptococcus pneumoniae. Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris isolates, Haemophilus influenzae, H. aegyptius, Moraxella lacunata, Acinetobacter and some Neisseria species.

This medication has a broad FDA approval for "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Steroid-responsive ocular infections and inflammatory conditions, recommended:

  • Instill 1 drop into the conjunctival sac(s) every 4 – 6 hours. During the initial 24 – 48 hours, dosage may be increased to 1 drop every 2 hours. 
  • Frequency should be decreased gradually as warranted by improvement in clinical signs, but care should be taken not to discontinue therapy prematurely.
  • Not more than 20 mL should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in WARNINGS AND PRECAUTIONS (5) in package insert.

How Supplied:  
  • 5 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 36° – 77°F (2° – 25°C).
  • Protect from light.


TOBRAMYCIN (tobramycin (0.3%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antibiotics
Indications/Usage:

Indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany use.

This medication has a broad FDA approval for "external infections of the eye and its adnexa." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "external infections of the eye and its adnexa." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

External infections of the eye and its adnexa caused by susceptible bacteria:

►Mild to moderate disease:

  • Instill 1 – 2 drops into the affected eye(s) every 4 hours.

 ►Severe infections:

  • Instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.

How Supplied:  
  • 5 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 36° – 77°F (2°– 25°C).


TOBRAMYCIN/DEXAMETHASONE (tobramycin (0.3%) – dexamethasone (0.1%) ophthalmic suspension)
Prescription
Topical
Ophthalmic Suspension
Antibiotic–Steroid Combination Medications
Indications/Usage:

Indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. 

Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation.

They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies.

The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.

The particular anti-infective drug in this product is active against the following common bacterial eye pathogens:

Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains.

Streptococci, including some of the Group A beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae.

Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species.

This medication has a broad FDA approval for "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Steroid-responsive inflammatory ocular conditions:

  • Instill 1 or 2 drops into the conjunctival sac(s) every 4 – 6 hours. 
  • During the initial 24 – 48 hours, the dosage may be increased to 1 or 2 drops every 2 hours.
  • Frequency should be decreased gradually as warranted by improvement in clinical signs. Care should be taken not to discontinue therapy prematurely.
  • Not more than 20 mL should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS in package insert.

How Supplied:  
  • 2.5 mL bottles
  • 5 mL bottles
  • 10 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store suspension at 46° – 80°F (8° – 27°C).
  • Store suspension upright.
  • Shake suspension well before using.


TOBREX (tobramycin (0.3%) ophthalmic ointment; ophthalmic solution)
Prescription
Topical
Ointment
Ophthalmic Solution
Antibiotics
Indications/Usage:

Indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany use.

This medication has a broad FDA approval for "external infections of the eye and its adnexa." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "external infections of the eye and its adnexa." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

External infections of the eye and its adnexa caused by susceptible bacteria:

►Mild to moderate disease:

  • Ophthalmic ointment:
    • Instill a ½ inch ribbon into the affected eye(s) 2 – 3 times per day.
  • Ophthalmic solution:
    • Instill 1 – 2 drops into the affected eye(s) every 4 hours.

 ►Severe infections:

  • Ophthalmic ointment:
    • Instill a ½ inch ribbon into the affected eye(s) every 3 – 4 hours until improvement, following which treatment should be reduced prior to discontinuation.
  • Ophthalmic solution:
    • Instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.

Additional information for applying TOBREX® (tobramycin ophthalmic ointment) is included in Notes below.


How Supplied:  
  • Ophthalmic ointment:
    • 3.5 g tubes
  • Ophthalmic solution:
    • 5 mL bottles

Preservatives:  

chlorobutanol (ophthalmic ointment); benzalkonium chloride (ophthalmic solution)


Storage:  
  • Ophthalmic ointment:
    • Store at 46°– 80°F (8°– 27°C).
  • Ophthalmic solution:
    • Store at 36° – 77°F (2°– 25°C).


TRAVATAN Z (travoprost (0.004%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Prostaglandin Analogs
Indications/Usage:

Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension.


Typical Dosing:  

Elevated intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension, recommended:

  • Instill 1 drop in the affected eye(s) once daily in the evening.
  • Should not be administered more than 1 time daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the IOP-lowering effect.
  • Reduction of the IOP starts approximately 2 hours after the first administration with maximum effect reached after 12 hours.
  • May be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

How Supplied:  
  • 2.5 mL bottles
  • 5 mL bottles

Preservatives:  

sofZia® (boric acid, propylene glycol, sorbitol, zinc chloride)


Storage:  
  • Store at 36° – 77°F (2° – 25°C)


Assistance: Payment Assistance

TRAVOPROST (travoprost (0.004%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Prostaglandin Analogs
Indications/Usage:

Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension.


Typical Dosing:  

Elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, recommended:

  • Instill 1 drop in the affected eye(s) once daily in the evening.
  • Should not be administered more than 1 time daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the IOP-lowering effect.
  • Reduction of IOP starts approximately 2 hours after the first administration with maximum effect reached after 12 hours.
  • May be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

How Supplied:  
  • 2.5 mL bottles
  • 5 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 36º – 77ºF (2º – 25ºC).


TRIAMCINOLONE (triamcinolone acetonide (0.025%; 0.1%; 0.5%) topical cream)
Prescription
Topical
Cream
Allergy Corticosteroids, Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

This medication has a broad FDA approval for "inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Eyelid dermatitis (allergic, eczematous, or xeroderma):

  • Apply to the affected area as a thin film 2 – 4 times daily depending on the severity of the condition.
  • Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressing should be discontinued and appropriate antimicrobial therapy instituted.

How Supplied:  
  • 0.025% topical cream:
    • 15 g tubes
    • 80 g tubes
    • 454 g tubes
  • 0.1% topical cream:
    • 15 g tubes
    • 30 g tubes
    • 80 g tubes
    • 454 g tubes
  • 0.5% topical cream:
    • 15 g tubes

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).


TRIESENCE (triamcinolone acetonide (4%) ophthalmic injection suspension)
Prescription
Injectable
Intravitreal
Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated for sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Also indicated for visualization during vitrectomy.


Typical Dosing:  

►Treatment of ophthalmic diseases, recommended:

  • Initial dose of 4 mg (100 microliters of 40 mg/mL suspension) with subsequent dosage as needed over the course of treatment.
  • Additional information for Administration is in Notes below.

►Visualization during vitrectomy:

  • Initial dose of 1 – 4 mg (25 – 100 microliters of 40 mg/mL suspension) administered intravitreally.
  • Additional information for Administration is in Notes below.

How Supplied:  
  • 1 mL single-use vials

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 39° – 77°F (4° – 25°C).
  • Do not freeze.
  • Protect from light by storing in carton.


TRIFLURIDINE (trifluridine (1%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antivirals
Indications/Usage:

Indicated for the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types 1 and 2.


Typical Dosing:  

Primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types 1 and 2:

  • Instill 1 drop onto the cornea of the affected eye every 2 hours while awake for a maximum daily dosage of 9 drops until the corneal ulcer has completely re-epithelialized.
  • Following re-epithelialization, treatment for an additional 7 days of 1 drop every 4 hours while awake for a minimum daily dosage of 5 drops is recommended.
  • If there are no signs of improvement after 7 days of therapy or complete re-epithelialization has not occurred after 14 days of therapy, other forms of therapy should be considered. Continuous administration of trifluridine for periods exceeding 21 days should be avoided because of potential ocular toxicity.

How Supplied:  
  • 7.5 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store under refrigeration 36° – 46°F (2° – 8°C).


TRIMETHOPRIM/POLYMYXIN B (trimethoprim sulfate (0.1%) – polymyxin B sulfate (10,000 units/mL) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antibiotics
Indications/Usage:

Indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis and blepharoconjunctivitis caused by susceptible strains of the following microorganisms: Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae; Streptococcus viridan; Haemophilus influenzae; Pseudomonas aeruginosa*.

*Efficacy for this organism in this organ system was studied in fewer than 10 infections.

This medication has a broad FDA approval for "surface ocular bacterial infections." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "surface ocular bacterial infections." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Mild to moderate surface ocular bacterial infections:

  • Instill 1 drop in the affected eye(s) every 3 hours (maximum of 6 doses per day) for a period of 7 – 10 days.

How Supplied:  
  • 10  mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 59˚ – 77˚F (15˚ – 25˚C).
  • Protect from light.


TROPICAMIDE (tropicamide (0.5%; 1%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Cycloplegics
Indications/Usage:

Indicated for mydriasis and cycloplegia for diagnostic procedures.


Typical Dosing:  

Refraction: 

  • Instill 1 or 2 drops of 1% solution in the eye(s), repeated in 5 minutes. If patient is not seen within 20 – 30 minutes, an additional drop may be instilled to prolong mydriatic effect.
  • Individuals with heavily pigmented irides may require higher strength or more doses.
  • Mydriasis will reverse spontaneously with time, typically in 4 – 8 hours. However, in some cases, complete recovery may take up to 24 hours.

Examination of fundus: 

  • For examination of fundus, instill 1 or 2 drops of 0.5% solution 15 – 20 minutes prior to examination.
  • Individuals with heavily pigmented irides may require higher strength or more doses.
  • Mydriasis will reverse spontaneously with time, typically in 4 – 8 hours. However, in some cases, complete recovery may take up to 24 hours.

How Supplied:  
  • 0.5% ophthalmic solution
    • 15 mL bottles
  • 1% ophthalmic solution 
    • 2 mL bottles
    • 3 mL bottles
    • 15 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Do not refrigerate or store at high temperatures.
  • Keep container tightly closed.


TRUSOPT (dorzolamide hydrochloride (2%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Carbonic Anhydrase Inhibitors
Indications/Usage:

Indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.


Typical Dosing:  

Elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma:

  • InstIll 1 drop in the affected eye(s) 3 times daily.
  • May be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

How Supplied:  
  • 10 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59° – 86°F (15° – 30°C).
  • Protect from light.


Assistance: Payment Assistance

TYLENOL EXTRA STRENGTH (acetaminophen (500 mg) tablets; (500 mg) capsules)
Over the Counter
Oral
Capsules
Tablets
Acetaminophen
Indications/Usage:

Temporarily relieves minor aches and pains and temporarily reduces fever.


Typical Dosing:  

Minor aches and pains or fever:

  • Do not take more than directed (see overdose warning in package insert).
  • Adults and children  12 years of age:
    • Take 2 tablets or capsules every 6 hours while symptoms last.
    • Do not take > 6 tablets or capsules in 24 hours, unless directed by a doctor.
    • Do not use for > 10 days unless directed by a doctor.
  • Children < 12 years:
    • Ask a doctor.

How Supplied:  
  • 500 mg capsules
  • 500 mg tablets

Preservatives:  

None listed in package insert.


Storage:  
  • Store between 68° – 77°F (20° – 25°C).


TYLENOL REGULAR STRENGTH (acetaminophen (325 mg) tablets; (325 mg) capsules)
Over the Counter
Oral
Capsules
Tablets
Acetaminophen
Indications/Usage:

Temporarily relieves minor aches and pains and temporarily reduces fever.


Typical Dosing:  

Minor aches and pains or fever:

  • Do not take more than directed (see overdose warning in package insert).
  • Adults and children  12 years of age:
    • Take 2 tablets or capsules every 4 – 6 hours while symptoms last.
    • Do not take > 10 tablets or capsules in 24 hours, unless directed by a doctor.
    • Do not use for > 10 days unless directed by a doctor.
  • Children 6 years to < 12 years:
    • Take 1 tablet or capsule every 4 – 6 hours while symptoms last.
    • Do not take > 5 tablets or capsules in 24 hours, unless directed by a doctor.
    • Do not use for > 5 days unless directed by a doctor.
  • Children < 6 years:
    • Ask a doctor.

How Supplied:  
  • 325 mg capsules
  • 325 mg tablets

Preservatives:  

None listed in package insert.


Storage:  
  • Store between 68° – 77°F (20° – 25°C).


TYLENOL WITH CODEINE (acetaminophen (300 mg) – codeine phosphate (30 mg; 60 mg) tablets)
Opioid
Prescription
Oral
Tablets
Opiates/Opioids
Indications/Usage:

Indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate.

Limitations of Use

Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses (See WARNINGS in package insert), reserve TYLENOL® with Codeine tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]

  • Have not provided adequate analgesia, or are not expected to provide adequate analgesia.
  • Have not been tolerated, or are not expected to be tolerated.

Typical Dosing:  

Mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate:

  • Initial dosage:
    • Dosage should be adjusted according to severity of pain and response of the patient. However, it should be kept in mind that tolerance to codeine can develop with continued use and that the incidence of untoward effects is dose related.
    • Adult doses of codeine higher than 60 mg are associated with an increased incidence of adverse reactions and are not associated with greater efficacy.
    • The usual adult dosage is:
      • TYLENOL with Codeine No. 3 tablets (codeine 30 mg and acetaminophen 300 mg):
        • Take 1 – 2 tablets every 4 hours as needed for pain.
      • TYLENOL with Codeine No. 4 tablets (codeine 60 mg and acetaminophen 300 mg):
        • Take 1 tablet every 4 hours as needed for pain.
    • The prescriber must determine the number of tablets per dose, and the maximum number of tablets per 24 hours, based upon the following dosage guidance. This information should be conveyed in the prescription.
      • Codeine phosphate:
        • Single Doses (Range): 30 – 60 mg. 
        • Maximum 24-hour Dose: 350 mg.
      • Acetaminophen:
        • Single Doses (Range): 300 mg – 1,000 mg.
        • Maximum 24-hour Dose: 4,000 mg.
    • Conversion from other opioids: There is inter-patient variability in the potency of opioid drugs and opioid formulations. Therefore, a conservative approach is advised when determining the total daily dosage of TYLENOL with Codeine tablets. It is safer to underestimate a patient's 24-hour TYLENOL with Codeine tablets dosage than to overestimate the 24-hour TYLENOL with Codeine tablets dosage and manage an adverse reaction due to overdose.
  • Titration and maintenance of therapy:
    • Individually titrate TYLENOL with Codeine tablets to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving TYLENOL with Codeine tablets to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse (See WARNINGS in package insert). Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.
    • If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the TYLENOL with Codeine tablets dosage. If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.
  • Safe reduction or discontinuation of TYLENOL with Codeine:
    • Do not abruptly discontinue TYLENOL with Codeine tablets in patients who may be physically dependent on opioids. Rapid discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances.
    • When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking TYLENOL with Codeine tablets, there are a variety of factors that should be considered, including the dose of TYLENOL with Codeine the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. It is important to ensure ongoing care of the patient and to agree on an appropriate tapering schedule and follow-up plan so that patient and provider goals and expectations are clear and realistic. When opioid analgesics are being discontinued due to a suspected substance use disorder, evaluate and treat the patient, or refer for evaluation and treatment of the substance use disorder. Treatment should include evidence-based approaches, such as medication assisted treatment of opioid use disorder. Complex patients with comorbid pain and substance use disorders may benefit from referral to a specialist.
    • There are no standard opioid tapering schedules that are suitable for all patients. Good clinical practice dictates a patient-specific plan to taper the dose of the opioid gradually. For patients on TYLENOL with Codeine tablets who are physically opioid-dependent, initiate the taper by a small enough increment (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks. Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper.
    • It may be necessary to provide the patient with lower dosage strengths to accomplish a successful taper. Reassess the patient frequently to manage pain and withdrawal symptoms, should they emerge. Common withdrawal symptoms include restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. If withdrawal symptoms arise, it may be necessary to pause the taper for a period of time or raise the dose of the opioid analgesic to the previous dose, and then proceed with a slower taper. In addition, monitor patients for any changes in mood, emergence of suicidal thoughts, or use of other substances.
    • When managing patients taking opioid analgesics, particularly those who have been treated for a long duration and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper. A multimodal approach to pain management may optimize the treatment of chronic pain, as well as assist with the successful tapering of the opioid analgesic (See WARNINGS/Withdrawal, DRUG ABUSE AND DEPENDENCE in package insert).
  • Additional important Dosage and Administration instructions in Notes below.

How Supplied:  
  • Tylenol with Codeine No. 3 tablets:
    • 300 mg acetaminophen – 30 mg codeine phosphate per tablet
  • Tylenol with Codeine No. 4 tablets:
    • 300 mg acetaminophen – 60 mg codeine phosphate per tablet

Preservatives:  

sodium metabisulfite


Storage:  
  • Store at 68° – 77°F (20° – 25°C).


ULTRACET (tramadol hydrochloride (37.5 mg) – acetaminophen (325 mg) tablets)
Opioid
Prescription
Oral
Tablets
Opiates/Opioids
Indications/Usage:

Indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Limitations of Use:

ULTRACET tablets are indicated for short-term use of 5 days or less.

Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [See Warnings and Precautions (5.1) in package insert], reserve ULTRACET for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]:

  • Have not been tolerated, or are not expected to be tolerated.
  • Have not provided adequate analgesia, or are not expected to provide adequate analgesia.
This medication has a broad FDA approval for "pain severe enough to require an opioid analgesic." Under our interpretation of this indication we have linked this medication with conditions we understand may be associated with "pain severe enough to require an opioid analgesic." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate, recommended:

  • Initial dosage:
    • 2 tablets every 4 – 6 hours as needed for pain relief up to a maximum of 8 tablets per day.
  • Dosage modification in patients with renal impairment:
    • In patients with CrCl < 30 mL/min, do not exceed 2 tablets every 12 hours.
  • Safe reduction or discontinuation of ULTRACET:
    • Do not abruptly discontinue ULTRACET in patients who may be physically dependent on opioids. Rapid discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances.
    • When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking ULTRACET, there are a variety of factors that should be considered, including the dose of ULTRACET the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. It is important to ensure ongoing care of the patient and to agree on an appropriate tapering schedule and follow-up plan so that patient and provider goals and expectations are clear and realistic. When opioid analgesics are being discontinued due to a suspected substance use disorder, evaluate and treat the patient, or refer for evaluation and treatment of the substance use disorder. Treatment should include evidence-based approaches, such as medication assisted treatment of opioid use disorder. Complex patients with comorbid pain and substance use disorders may benefit from referral to a specialist.
    • There are no standard opioid tapering schedules that are suitable for all patients. Good clinical practice dictates a patient-specific plan to taper the dose of the opioid gradually. For patients on opioids who are physically opioid-dependent, initiate the taper by a small enough increment (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and use a gradual downward taper. Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper.
    • It may be necessary to provide the patient with lower dosage strengths to accomplish a successful taper. Reassess the patient frequently to manage pain and withdrawal symptoms, should they emerge. Common withdrawal symptoms include restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. If withdrawal symptoms arise, it may be necessary to pause the taper for a period of time or raise the dose of the opioid analgesic to the previous dose, and then proceed with a slower taper. In addition, monitor patients for any changes in mood, emergence of suicidal thoughts, or use of other substances.
    • When managing patients taking opioid analgesics, particularly those who have been treated for a long duration and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper. A multimodal approach to pain management may optimize the treatment of chronic pain, as well as assist with the successful tapering of the opioid analgesic [See Warnings and Precautions (5.20), Drug Abuse and Dependence (9.3).
  • Additional important Dosage and Administration instructions in Notes below.

How Supplied:  
  • 325 mg acetaminophen and 37.5 mg tramadol hydrochloride tablets

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Excursions permitted to 59° – 86° F (15° – 30°C).
  • Store securely and dispose of properly [See Patient Counseling Information (17) in package insert].


227 items found